3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
11
Phase 2
3
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Recurrence
1
Interventions
pembrolizumab
3
venetoclax
2
selpercatinib
2
obinutuzumab
2
ibrutinib
2
decitabine and cedazuridine drug combination
2
cedazuridine
2
Rituximab
2
Nivolumab
2
Midazolam
2
Ipilimumab
2
Decitabine
2
Crizotinib
2
zanubrutinib
1
trametinib
1
toripalimab
1
tocilizumab
1
tazemetostat
1
tagraxofusp
1
sotorasib
1
sacituzumab govitecan
1
romiplostim
1
revumenib
1
repotrectinib
1
prednisolone phosphate
1
prednisolone acetate
1
pralsetinib
1
polatuzumab vedotin
1
pirtobrutinib
1
olutasidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Has announcements
×
Cyclophosphamide
×
Clear all
NCT02614066
2024-11-19
ZUMA-3
Gilead Sciences
Phase 1/2
Completed
125 enrolled
27 charts
1 FDA